What is Diabetic Macular Edema Treatment Market?
Advancements in ophthalmic surgery techniques, as well as pharmaceutical companies' R&D investments, will help to fuel numerous opportunities for the diabetic macular edema treatment market to expand. Diabetic macular edema (DME) is a buildup of fluid in the macula of the retina, which regulates the human eye's vision abilities. Diabetic retinopathy is a condition that is caused by DME. DME is one of the most common complications of diabetes, and DME patients use considerably more healthcare services than diabetic patients who do not have DME.
The market study is being classified by Type (Laser Photocoagulation Therapy, Pharmacological Therapy, Bevacizumab, Ranibizumab and Triamcinolone) and major geographies with country level break-up.
F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline plc (United Kingdom), Alimera Sciences, Inc. (United States), Allergan, Inc (Ireland), Regeneron Pharmaceuticals Inc. (United States), Pfizer Inc. (United States), Kubota Pharmaceutical Holdings Co. Ltd. (United States), Oculis (Switzerland) and Bayer AG (Germany) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Bausch & Lomb Incorporated (United States) and Jaeb Center for Health Research (United States).
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Diabetic Macular Edema Treatment market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Diabetic Macular Edema Treatment market by Type, Application and Region.
On the basis of geography, the market of Diabetic Macular Edema Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Prevalence of Diabetes
- Rising Awareness for the Treatment of Diabetic Macular Edema
- Surging R&D Investment by Pharmaceutical Companies in the Diabetic Macular Edema Treatment Field
- High Medical Costs for the Patients
- Lucrative Opportunities in the Emerging Economies
- Advancement in Ophthalmic Surgery Techniques
- Dearth of Skilled Ophthalmologists
- Extended Approval Time for Drugs
Market Leaders and some development strategies
December 20, 2020, Genentech announced positive topline results from two identically designed global Phase III studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME)
In Jan 2021, AsclepiX Therapeutics, Inc announced that the first patient has been dosed in the Phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with Diabetic Macular Edema (DME)., and In Dec 2020, Novartis announced positive findings from the first interpretable results of the Phase III KESTREL study, assessing the efficacy and safety of Beovu® (brolucizumab) 3 mg and 6 mg in diabetic macular edema (DME).
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Diabetic Macular Edema Treatment Providers, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase